Retrieve available abstracts of 29 articles: HTML format
Single Articles
June 2025
GUPTA S, Rau RE, Loh ML Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply.
N Engl J Med. 2025;392:2286-2287. PubMed
HODDER A, Vora A, Samarasinghe S Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia.
N Engl J Med. 2025;392:2286. PubMed
BROWN JR, Miller K, Munugalavadla V Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic
Leukemia. Reply.
N Engl J Med. 2025;392:2181. PubMed
MOHTY M, Kharfan-Dabaja MA Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic
Leukemia.
N Engl J Med. 2025;392:2180-2181. PubMed
May 2025
FOA R Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of Progress.
N Engl J Med. 2025;392:1941-1952. PubMed
April 2025
SANTI A, Venanzi A, Pucciarini A, Schiavoni G, et al Targetable Mutations in BRAF V600E-Negative Hairy-Cell Leukemia.
N Engl J Med. 2025;392:1451-1452. PubMed
February 2025
BROWN JR, Seymour JF, Jurczak W, Aw A, et al Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic
Leukemia.
N Engl J Med. 2025;392:748-762. PubMedAbstract available
January 2025
BASHIR BA Chronic Myeloid Leukemia with Hyperleukocytosis.
N Engl J Med. 2025;392:72. PubMed
December 2024
FALINI B, Tiacci E Hairy-Cell Leukemia. Reply.
N Engl J Med. 2024;391:2388. PubMed
HERMEL DJ, Saven A Hairy-Cell Leukemia.
N Engl J Med. 2024;391:2387-2388. PubMed
REINHOLD I, Cornely OA, Stemler J Hairy-Cell Leukemia.
N Engl J Med. 2024;391:2386-2387. PubMed
ABRUZZESE E Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
N Engl J Med. 2024;391:2276. PubMed
HOCHHAUS A, Cortes JE, Hughes TP Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
N Engl J Med. 2024;391:2275-2276. PubMed
PUNWANI N Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med. 2024;391:2275. PubMed
GAMBACORTI-PASSERINI C, Piazza R Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med. 2024;391:2274-2275. PubMed
GUPTA S, Rau RE, Kairalla JA, Rabin KR, et al Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
N Engl J Med. 2024 Dec 7. doi: 10.1056/NEJMoa2411680. PubMedAbstract available
November 2024
RODDIE C, Sandhu KS, Tholouli E, Logan AC, et al Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
N Engl J Med. 2024 Nov 27. doi: 10.1056/NEJMoa2406526. PubMedAbstract available
October 2024
FALINI B, Tiacci E Hairy-Cell Leukemia.
N Engl J Med. 2024;391:1328-1341. PubMed
September 2024
ABRUZZESE E CML 25 Years Later - Poised for Another Breakthrough?
N Engl J Med. 2024;391:955-957. PubMed
August 2024
HSU C, Konner JA, Gounder MM Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.
N Engl J Med. 2024;391:770-772. PubMed
July 2024
LITZOW MR, Sun Z, Mattison RJ, Paietta EM, et al Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
N Engl J Med. 2024;391:320-333. PubMedAbstract available
June 2024
TIONG IS, Ritchie DS, Blombery P Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML.
N Engl J Med. 2024;390:2323-2325. PubMed
May 2024
HOCHHAUS A, Wang J, Kim DW, Kim DDH, et al Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med. 2024 May 31. doi: 10.1056/NEJMoa2400858. PubMedAbstract available
MUNIR T, Hillmen P Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Reply.
N Engl J Med. 2024;390:1634-1635. PubMed
WANG WD, Gale RP, Liang Y Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med. 2024;390:1633-1634. PubMed
WINKLER C Acute Promyelocytic Leukemia.
N Engl J Med. 2024;390:e42. PubMed
April 2024
BLAISE D CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
N Engl J Med. 2024;390:1526-1527. PubMed
HU Y, Zhang M, Yang T, Mo Z, et al Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
N Engl J Med. 2024;390:1467-1480. PubMedAbstract available
December 2023
MUNIR T, Cairns DA, Bloor A, Allsup D, et al Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med. 2023 Dec 10. doi: 10.1056/NEJMoa2310063. PubMedAbstract available